H eart failure (HF) is often complicated by electrolyte abnormalities. As ventricular dysfunction progresses to symptomatic HF, up-regulation of maladaptive neurohormonal systems may limit solute and free water delivery to the distal nephron, increasing free water absorption and potentially reducing serum sodium and chloride levels (1, 2) . These electrolyte perturbations may be exacerbated through the use of decongestive therapies in acute and chronic HF (e.g., loop and thiazide diuretics) (3) (4) (5) . The finding of hyponatremia in the patient with HF is a well-established, strong predictor of short-and long-term morbidity and mortality irrespective of left ventricular (LV) systolic function (6) (7) (8) (9) (10) (11) (12) (13) .
However, the impact of hypochloremia in HF is less well understood despite its broad availability in routinely used blood chemistry panels and its com- Patients were excluded if they were not given a loop diuretic during admission, did not have an active medication list, were <18 years of age, had prior heart transplantation or mechanical circulatory assist device, or were on chronic dialysis therapy. Only the first admission for a patient was included in the cohort if they were subsequently readmitted. Longterm all-cause mortality was determined from the electronic medical record and validated, if possible, by the Social Security Death Index. All patients were followed until December 31, 2013.
VALIDATION COHORT. Charts of consecutive admissions to noninterventional cardiology or internal medicine services at the Hospital of the University of Pennsylvania from 2004 to 2009 were reviewed. The assembly and characteristics of patients in this cohort have been previously described (14, 15) . Briefly, inclusion required a primary discharge diagnosis of congestive HF, a hospital admission length between 3 and 14 days, and a B-type natriuretic peptide level >100 pg/ml within 24 h of admission. Patients on renal-replacement therapy were excluded from analysis, as were patients without documentation of specific HF etiology, available blood chemistry values at admission, or baseline medication use information.
As in the derivation cohort, in the case of multiple admissions for a single patient, only the first admission was included. Clinical, demographic, imaging, and laboratory data, and documented primary and secondary diagnoses were reviewed from the electronic medical record. Admission chloride was defined as the level on first blood draw on presentation; discharge chloride was determined using the blood draw on the day of discharge. All patients were followed until June 30, 2012, and death was verified by the Social Security Death Index. inhibitor use, and mineralocorticoid antagonist use peptide) and indicators of end-organ function (he- (17, 18) . The discrimination (C statistic) of the impact of moglobin and bilirubin). They were also inversely chloride levels on mortality was deter-mined as related to length of stay in the hospital and net weight previously described (19) . Category-free net-change during admission. reclassification indexes and integrated discrimi-CHLORIDE LEVELS AND ALL-CAUSE MORTALITY. The nation improvement were calculated to further clarify Cleveland Clinic cohort of l ,3l 8 patients had 2, 261 the incremental prognostic value of chloride (20) . Double-sided p values < 0.05 were considered statistically significant. Statistical analyses were performed using Stata version 13.1 software (Stata-Corp LP, College Station, Texas).
RESULTS
person-years of follow-up for all-cause mortality. There were 359 deaths over a median follow-up time of 1.47 (interquartile range: 0.51 to 2.68) years. Kaplan-Meier survival estimates were different across tertiles of admission chloride level (log-rank p < 0.001 for all) (Central Illustration). There were 164, 127, and 68 deaths for tertiles 1 to 3, respectively. BASELINE CHARACTERISTICS. Baseline characteris-Tertile 1 had a higher death incidence rate of tics for the Cleveland Clinic and University of Penn-0.22 death/person-years compared with tertiles sylvania cohorts are shown in Tables 1 and 2 , respectively. For the Cleveland Clinic cohort, admission chloride levels were normally distributed, with median and mean admission chloride being 101 (interquartile range: 97 to 104) mEq/1 and 100 ± 6 mEq/1, 2 and 3 with 0.14 and 0.10 death/person-years, respectively.
Per the univariable and multivariable proportional hazards models (Table 3) , admission chloride levels were inversely associated with mortality (p < 0.001). respectively. As expected, admission chloride levels Every unit increase in chloride was associated with an were directly correlated to admission sodium levels (p o.61; p < 0.001) and negatively correlated to admission bicarbonate levels (p 0.39; p < 0.001). Higher chloride levels were positively associated with increasing LV ejection fraction, beta-blocker and renin-angiotensin system-blocker use, and renal dysfunction, but negatively associated with markers of neurohormonal activation (blood urea nitrogen and N-terminal pro-B-type natriuretic -6% relative improvement in survival (HR per unit change: 0.94; 95% CI: 0.92 to 0.95; p < 0.001). Although admission sodium levels were also inversely associated with mortality (HR per unit change: 0.95; 95% CI: 0.93 to 0.97; p < 0.001), admission chloride levels showed greater discrimination for mortality (C statistic: o.60; 95% CI: 0.57 to o.64) than admission sodium levels (C statistic: 0.56; 95% CI: 0.53 to 0.59; p < 0.001). There was no Figure 1 , which graphically illustrates that chloride levels may have a stronger prognostic role than sodium levels. After multivariable adjustment, admission chloride levels remained independently inversely associated with mortality (HR per unit change: 0.93; 95% CT: 0.90 to 0.97; p < 0.001) (Figure 2) . Mortality risk increased with decreasing chloride levels below -96 mEq/1 and did not significantly differ at values >96 mEq/1. There was no increase in the overall C statistic of the multivariable model with the addition of chloride (o.68 vs. o.69; p 0.5). However, adding chloride to the multivariable model did significantly reclassify risk (integrated discrimination improvement, 10%; p < 0.001; category-free netreclassification indexes, 17.2%; p 0.006). With additional adjustment for weight change and blood urea nitrogen/creatinine ratio, admission chloride levels remained significantly associated with mortality (HR per unit change: 0.93; 95% CI: 0.90 to 0.97; p < 0.001). However, after multivariable adjustment for other variables including admission chloride levels, admission sodium levels were not independently associated with mortality (HR per unit change: 1.03; 95% CT: 0.99 to 1.07; p 0.18). Discharge chloride level was significant when substituted for admission chloride level (discharge sodium level was substituted for admission sodium level) in the multivariable model for mortality (HR per unit change: 0.94; 95% CT: 0.92 to 0.97; p < 0.001) and is graphically depicted in Figure 3 .
To validate our present findings, we turned to an independent acute HF cohort from the University of Pennsylvania with longer follow-up (Table 3 ). Admission chloride distribution was comparable with our study cohort (median: 103 [100 to 106) mEq/1; mean: 103 ± 6 mEq/l). Baseline characteristics of this validation cohort are presented in Table 2 . Similar to the Cleveland Clinic cohort, admission chloride levels were directly correlated to admission sodium (p 0.54; p < 0.001) and negatively correlated to admission bicarbonate levels (p ·0.49; p < 0.001). There were 453 deaths out of 876 patients with 3,038 person-years of follow-up for all-cause mortality. In contrast to the derivation cohort, admission chloride levels violated the proportional hazards assumption (p > 0.1) and were thus analyzed as a Heaviside function with time stratified at 1 year. Admission chloride levels were inversely associated with 1-year mortality in unadjusted ( Kaplan Meier survival curve estimates d.assified by levels of chloride (< or a:96 mEq/l} and sodium(< or a:134 mEq/0 on admission demonstrate that chloride levels may provide a stronger prognosis role than sodium levels. 0_96 to 1-03; p 0.58). Similar to the Cleveland Clinic cohort, discharge chloride level was significant when substituted for admission chloride level (discharge sodium level was substituted for admission sodium level) to the multivariable model for mortality (HR per unit change: 0.97; 95% CI: 0.95 to 0.99; p 0.01).
DISCUSSION
In 2 contemporary cohorts of patients predominantly with systolic dysfunction hospitalized for A fitted curve was generated from residual estimates according to discharge chloride level at t he Cleveland CUnic after multi variable adjustment for sodium, length of stay, bicarbonate, blood urea nitrogen, age, ischemic cardiomyopathy, and drug use (beta blocker, renin angiotensin system blocker, and mineralo corticoid antagonist). Cl confidence interval.
ADHF and electrolyte measures, we report several key findings that highlight prognostic implications of serum chloride. First, serum chloride levels were independently and inversely associated with mortality after multivariable adjustment for other prognostic factors including serum sodium concentration. Second, serum chloride levels modestly enhanced mortality prediction compared with sodium levels. Furthermore, serum sodium levels were no longer associated with mortality when serum chloride levels were added to the multivariable model. Finally, although modestly correlated, serum chloride and serum sodium levels had no significant interaction for mortality prediction. These findings highlight the prognostic implications of serum chloride level in ADHF and suggest that it provides stronger prognostic information than serum sodium level. Further investigations into the clinical relevance of hypochloremia in the setting of acute HF are warranted. The pathological role of chloride in HF is incompletely understood, in part because chloride levels have been rarely documented in clinical trials or registries. Chloride accounts for approximately onethird of the tonicity and two-thirds of all negative charges in the plasma (21) . Dietary sodium chloride is the main source of chloride in the body and its removal is facilitated by gastric, sweat, and renal excretion. Serum chloride levels may represent the downstream effects of adversely prognostic maladaptive neurohormonal, renal, and acid-base disturbances in HF. Indeed, mechanisms that reduce sodium levels can similarly lower chloride levels (22) . These include: 1) the pathological impairment of free water excretion resulting from increased nonosmotic release of arginine vasopressin (23) , which is typically increased in patients with symptomatic HF (24, 25) ; 2) the pleotropic effects of excess angiotensin II on renal sodium and water handling and neural thirst center activation (1); and 3) increased baroreceptor-mediated release of arginine vasopressin (24) . All of these mechanisms are directly stimulated in HF (26) . As a result, lower chloride levels may be dilutional in nature. Yet they may also represent a state of electrolyte depletion, especially when chloride is lower relative to sodium, which can occur in the setting of diuretic-induced salt wasting as chloride is excreted in the urine while bicarbonate is retained to maintain electroneutrality (27) . Making this distinction may have clinical implications when administering decongestive therapies for acute HF (28) .
Both sodium and chloride levels were prognostically similar in unadjusted, but not adjusted, analyses, potentially suggesting a pathophysiolog-ical with ADHF and established HF based on the history difference in the 2 electrolytes. In the presence of HF, of an ICD. Data were Jacking regarding patient-level the relative concentrations of sodium and chloride in decision making and resulting medication changes the plasma compartments can be Jow-ered and the impact they would have on changing chlosymmetrically or asymmetrically (29, 30) . This may ride levels and prognosis. Similarly, the impact of be related to the ability of the kidney to excrete these chloride levels on HF rehospitalizations could not be electrolytes and modified by thera-peutic measures determined. There was only a minority of patients (loop diuretics) and comorbid conditions. Chloride is a with serum chloride levels >107 mEq/1, and this buffer for cations, in-eluding acid and sodium, and analysis was underpowered to determine increased plays a major role in the ability of the kidney to risk caused by hyperchloremia. To our knowledge, eliminate salt and water. Therefore, in contrast to sodium, chloride has a stronger prognostic role because it may play a broader homeostatic role.
Our finding that lower chloride levels during admission were associated with higher mortality offers important insights into interpretation of electrolytes in ADHF. Our findings suggest that although however, therapies that increase serum chloride concentrations, such as hypertonic saline, are rarely used in ADHF populations, but the potential impact of potassium supplementation with potassium chloride is unclear. Nevertheless, this large, wellpowered ADHF cohort confers a new perspective on serum chloride levels and their impact on sodium levels are important, more robust prognostic prognosis. information can be inferred from serum chloride levels. Although low sodium has consistently been shown to CONCLUSIONS be a strong predictor of short-and Jong-term morbidity and mortality in patients with both systolic and Serum chloride levels measured during hospitalizadiastolic HF (7,u,13,31,32) , there was little tion for ADHF are independently and inversely assomention of the impact of chloride on the interpretation dated with Jong-term mortality. This association was of sodium levels in these analyses. As our results independent of, and added incremental prognostic suggest, these previous results may have failed to take information to, serum sodium levels. These findings into account serum chloride levels. highlight the clinical significance of chloride, a rou-Prior evidence for the prognostic role of chloride is tinely measured electrolyte, in Jong-term prognostisparse, and there is no formalized definition of cation for ADHF. hypochlorernia in HF. Our observations highlight the need to focus on better understanding of chloride homeostasis and preserving it as a potential thera-REPRINT REQUESTS AND CORRESPONDENCE: Dr. peutic consideration, particularly in the setting of W.R. Wilson Tang, Heart and Vascular Institute, ADHF with extensive use of loop diuretics that Cleveland Clinic, 9500 Euclid Avenue, Desk 13-4, primarily inhibit the sodium-potassium-chloride Cleveland, Ohio 44195. E-mail: tangw@ccf.org OR cotransporter leading to inevitable and excessive Dr. Jeffrey M. Testani, Yale University, 60 Temple chloride wasting.
Street, Suite 6C, New Haven, Connecticut 06510.
STUDY LIMITATIONS_ Our results must be inter-preted in the context of several limitations in our study design. We cannot exclude the presence of selection b ias for those undergoing evaluation and treatment for ADHF at 2 tertiary care centers. How-ever, the external validity of t hese findings is st-rengthened with the addition of the validation cohort. These patients largely had systolic dysfunc-tion with questionable generalizability to an ADHF population with preserved L V systolic function. Yet this also afforded an opportunity for a diversity of pathology in a contemporary cohort recorded by a modem electronic medical record to be retrieved in a very efficient manner. Our analysis also displayed a unique way of identifying patients presenting E-mail: jeffrey.testani@yale.edu. 
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